Pulmonale Hypertonie : was ist neu in der Therapie?
Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essentia...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sommer, Natascha - 1974- [verfasserIn] Weigand, Markus A. - 1967- [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Deutsch ; Englisch |
| Erschienen: |
4. August 2016 |
|---|
| Schlagwörter: |
Endothelin receptor antagonists Phosphodiesterase type 5 inhibitors |
|---|
| Anmerkung: |
Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 |
|---|---|
| Umfang: |
18 |
| Übergeordnetes Werk: |
Enthalten in: Der Anaesthesist - Berlin : Springer, 1994, 65(2016), 8, Seite 635-652 |
|---|---|
| Übergeordnetes Werk: |
volume:65 ; year:2016 ; number:8 ; pages:635-652 ; extent:18 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00101-016-0207-y |
|---|
| Katalog-ID: |
1581951477 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1581951477 | ||
| 003 | DE-627 | ||
| 005 | 20220815032133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181016s2016 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00101-016-0207-y |2 doi | |
| 035 | |a (DE-627)1581951477 | ||
| 035 | |a (DE-576)511951477 | ||
| 035 | |a (DE-599)BSZ511951477 | ||
| 035 | |a (OCoLC)1341020112 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger |a eng | ||
| 100 | 1 | |a Sommer, Natascha |d 1974- |e verfasserin |0 (DE-588)129248916 |0 (DE-627)391469665 |0 (DE-576)188399836 |4 aut | |
| 245 | 1 | 0 | |a Pulmonale Hypertonie |b was ist neu in der Therapie? |c N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall |
| 246 | 3 | 3 | |a Pulmonary hypertension$dwhat is new in therapy? |
| 264 | 1 | |c 4. August 2016 | |
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Paralleltitel von der Frontdoor übernommen | ||
| 500 | |a Mit engl. Zusammenfassung | ||
| 500 | |a Gesehen am 16.10.2018 | ||
| 520 | |a Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. | ||
| 650 | 4 | |a Endothelin receptor antagonists | |
| 650 | 4 | |a Endothelinrezeptorantagonist | |
| 650 | 4 | |a IP receptor agonist | |
| 650 | 4 | |a IP-Rezeptor-Agonist | |
| 650 | 4 | |a Lösliche Guanylatzyklase | |
| 650 | 4 | |a Phosphodiesterase type 5 inhibitors | |
| 650 | 4 | |a Phosphodiesterase-Typ-5-Inhibitor | |
| 650 | 4 | |a Prostacyclin | |
| 650 | 4 | |a Prostazyklin | |
| 650 | 4 | |a Soluble guanylyl cyclase | |
| 700 | 1 | |a Weigand, Markus A. |d 1967- |e verfasserin |0 (DE-588)1064970435 |0 (DE-627)815375239 |0 (DE-576)424658666 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Anaesthesist |d Berlin : Springer, 1994 |g 65(2016), 8, Seite 635-652 |h Online-Ressource |w (DE-627)253389771 |w (DE-600)1458421-9 |w (DE-576)072283122 |x 1432-055X |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2016 |g number:8 |g pages:635-652 |g extent:18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00101-016-0207-y |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00101-016-0207-y |x Verlag |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2339 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2016 |e 8 |h 635-652 |g 18 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3028880024 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 16-10-18 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2016 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_9 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_18 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1497922607 |a Weigand, Markus A. | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_6 | ||
| author_variant |
n s ns m a w ma maw |
|---|---|
| matchkey_str |
article:1432055X:2016----::umnlhp |
| oclc_num |
1341020112 |
| hierarchy_sort_str |
4. August 2016 |
| publishDate |
2016 |
| allfields |
10.1007/s00101-016-0207-y doi (DE-627)1581951477 (DE-576)511951477 (DE-599)BSZ511951477 (OCoLC)1341020112 DE-627 ger DE-627 rda ger eng Sommer, Natascha 1974- verfasserin (DE-588)129248916 (DE-627)391469665 (DE-576)188399836 aut Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall Pulmonary hypertension$dwhat is new in therapy? 4. August 2016 18 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase Weigand, Markus A. 1967- verfasserin (DE-588)1064970435 (DE-627)815375239 (DE-576)424658666 aut Enthalten in Der Anaesthesist Berlin : Springer, 1994 65(2016), 8, Seite 635-652 Online-Ressource (DE-627)253389771 (DE-600)1458421-9 (DE-576)072283122 1432-055X nnns volume:65 year:2016 number:8 pages:635-652 extent:18 http://dx.doi.org/10.1007/s00101-016-0207-y Verlag Resolving-System Volltext https://doi.org/10.1007/s00101-016-0207-y Verlag Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_267 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2339 GBV_ILN_2414 GBV_ILN_2424 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 65 2016 8 635-652 18 2013 01 DE-16-250 3028880024 00 --%%-- --%%-- --%%-- --%%-- l01 16-10-18 2013 01 DE-16-250 00 s hd2016 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_9 2013 01 DE-16-250 03 s s_18 2013 01 DE-16-250 04 p (DE-627)1497922607 Weigand, Markus A. 2013 01 DE-16-250 04 k (DE-627)1416740848 Chirurgische Universitätsklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_6 |
| spelling |
10.1007/s00101-016-0207-y doi (DE-627)1581951477 (DE-576)511951477 (DE-599)BSZ511951477 (OCoLC)1341020112 DE-627 ger DE-627 rda ger eng Sommer, Natascha 1974- verfasserin (DE-588)129248916 (DE-627)391469665 (DE-576)188399836 aut Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall Pulmonary hypertension$dwhat is new in therapy? 4. August 2016 18 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase Weigand, Markus A. 1967- verfasserin (DE-588)1064970435 (DE-627)815375239 (DE-576)424658666 aut Enthalten in Der Anaesthesist Berlin : Springer, 1994 65(2016), 8, Seite 635-652 Online-Ressource (DE-627)253389771 (DE-600)1458421-9 (DE-576)072283122 1432-055X nnns volume:65 year:2016 number:8 pages:635-652 extent:18 http://dx.doi.org/10.1007/s00101-016-0207-y Verlag Resolving-System Volltext https://doi.org/10.1007/s00101-016-0207-y Verlag Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_267 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2339 GBV_ILN_2414 GBV_ILN_2424 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 65 2016 8 635-652 18 2013 01 DE-16-250 3028880024 00 --%%-- --%%-- --%%-- --%%-- l01 16-10-18 2013 01 DE-16-250 00 s hd2016 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_9 2013 01 DE-16-250 03 s s_18 2013 01 DE-16-250 04 p (DE-627)1497922607 Weigand, Markus A. 2013 01 DE-16-250 04 k (DE-627)1416740848 Chirurgische Universitätsklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_6 |
| allfields_unstemmed |
10.1007/s00101-016-0207-y doi (DE-627)1581951477 (DE-576)511951477 (DE-599)BSZ511951477 (OCoLC)1341020112 DE-627 ger DE-627 rda ger eng Sommer, Natascha 1974- verfasserin (DE-588)129248916 (DE-627)391469665 (DE-576)188399836 aut Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall Pulmonary hypertension$dwhat is new in therapy? 4. August 2016 18 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase Weigand, Markus A. 1967- verfasserin (DE-588)1064970435 (DE-627)815375239 (DE-576)424658666 aut Enthalten in Der Anaesthesist Berlin : Springer, 1994 65(2016), 8, Seite 635-652 Online-Ressource (DE-627)253389771 (DE-600)1458421-9 (DE-576)072283122 1432-055X nnns volume:65 year:2016 number:8 pages:635-652 extent:18 http://dx.doi.org/10.1007/s00101-016-0207-y Verlag Resolving-System Volltext https://doi.org/10.1007/s00101-016-0207-y Verlag Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_267 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2339 GBV_ILN_2414 GBV_ILN_2424 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 65 2016 8 635-652 18 2013 01 DE-16-250 3028880024 00 --%%-- --%%-- --%%-- --%%-- l01 16-10-18 2013 01 DE-16-250 00 s hd2016 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_9 2013 01 DE-16-250 03 s s_18 2013 01 DE-16-250 04 p (DE-627)1497922607 Weigand, Markus A. 2013 01 DE-16-250 04 k (DE-627)1416740848 Chirurgische Universitätsklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_6 |
| allfieldsGer |
10.1007/s00101-016-0207-y doi (DE-627)1581951477 (DE-576)511951477 (DE-599)BSZ511951477 (OCoLC)1341020112 DE-627 ger DE-627 rda ger eng Sommer, Natascha 1974- verfasserin (DE-588)129248916 (DE-627)391469665 (DE-576)188399836 aut Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall Pulmonary hypertension$dwhat is new in therapy? 4. August 2016 18 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase Weigand, Markus A. 1967- verfasserin (DE-588)1064970435 (DE-627)815375239 (DE-576)424658666 aut Enthalten in Der Anaesthesist Berlin : Springer, 1994 65(2016), 8, Seite 635-652 Online-Ressource (DE-627)253389771 (DE-600)1458421-9 (DE-576)072283122 1432-055X nnns volume:65 year:2016 number:8 pages:635-652 extent:18 http://dx.doi.org/10.1007/s00101-016-0207-y Verlag Resolving-System Volltext https://doi.org/10.1007/s00101-016-0207-y Verlag Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_267 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2339 GBV_ILN_2414 GBV_ILN_2424 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 65 2016 8 635-652 18 2013 01 DE-16-250 3028880024 00 --%%-- --%%-- --%%-- --%%-- l01 16-10-18 2013 01 DE-16-250 00 s hd2016 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_9 2013 01 DE-16-250 03 s s_18 2013 01 DE-16-250 04 p (DE-627)1497922607 Weigand, Markus A. 2013 01 DE-16-250 04 k (DE-627)1416740848 Chirurgische Universitätsklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_6 |
| allfieldsSound |
10.1007/s00101-016-0207-y doi (DE-627)1581951477 (DE-576)511951477 (DE-599)BSZ511951477 (OCoLC)1341020112 DE-627 ger DE-627 rda ger eng Sommer, Natascha 1974- verfasserin (DE-588)129248916 (DE-627)391469665 (DE-576)188399836 aut Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall Pulmonary hypertension$dwhat is new in therapy? 4. August 2016 18 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase Weigand, Markus A. 1967- verfasserin (DE-588)1064970435 (DE-627)815375239 (DE-576)424658666 aut Enthalten in Der Anaesthesist Berlin : Springer, 1994 65(2016), 8, Seite 635-652 Online-Ressource (DE-627)253389771 (DE-600)1458421-9 (DE-576)072283122 1432-055X nnns volume:65 year:2016 number:8 pages:635-652 extent:18 http://dx.doi.org/10.1007/s00101-016-0207-y Verlag Resolving-System Volltext https://doi.org/10.1007/s00101-016-0207-y Verlag Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_267 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2339 GBV_ILN_2414 GBV_ILN_2424 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 65 2016 8 635-652 18 2013 01 DE-16-250 3028880024 00 --%%-- --%%-- --%%-- --%%-- l01 16-10-18 2013 01 DE-16-250 00 s hd2016 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_9 2013 01 DE-16-250 03 s s_18 2013 01 DE-16-250 04 p (DE-627)1497922607 Weigand, Markus A. 2013 01 DE-16-250 04 k (DE-627)1416740848 Chirurgische Universitätsklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_6 |
| language |
German English |
| source |
Enthalten in Der Anaesthesist 65(2016), 8, Seite 635-652 volume:65 year:2016 number:8 pages:635-652 extent:18 |
| sourceStr |
Enthalten in Der Anaesthesist 65(2016), 8, Seite 635-652 volume:65 year:2016 number:8 pages:635-652 extent:18 |
| format_phy_str_mv |
Article |
| building |
2013:0 |
| institution |
findex.gbv.de |
| selectbib_iln_str_mv |
2013@01 |
| topic_facet |
Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase |
| sw_local_iln_str_mv |
2013:hd2016 DE-16-250:hd2016 2013:wissenschaftlicher Artikel (Zeitschrift) DE-16-250:wissenschaftlicher Artikel (Zeitschrift) 2013:per_9 DE-16-250:per_9 2013:s_18 DE-16-250:s_18 2013:Weigand, Markus A. DE-16-250:Weigand, Markus A. 2013:Chirurgische Universitätsklinik DE-16-250:Chirurgische Universitätsklinik 2013:Verfasser DE-16-250:Verfasser 2013:pos_6 DE-16-250:pos_6 |
| isfreeaccess_bool |
false |
| container_title |
Der Anaesthesist |
| authorswithroles_txt_mv |
Sommer, Natascha @@aut@@ Weigand, Markus A. @@aut@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
253389771 |
| id |
1581951477 |
| language_de |
deutsch englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1581951477</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20220815032133.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181016s2016 xx |||||o 00| ||ger c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00101-016-0207-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1581951477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-576)511951477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ511951477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1341020112</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ger</subfield><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sommer, Natascha</subfield><subfield code="d">1974-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)129248916</subfield><subfield code="0">(DE-627)391469665</subfield><subfield code="0">(DE-576)188399836</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pulmonale Hypertonie</subfield><subfield code="b">was ist neu in der Therapie?</subfield><subfield code="c">N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall</subfield></datafield><datafield tag="246" ind1="3" ind2="3"><subfield code="a">Pulmonary hypertension$dwhat is new in therapy?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">4. August 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Paralleltitel von der Frontdoor übernommen</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Mit engl. Zusammenfassung</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Gesehen am 16.10.2018</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelinrezeptorantagonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IP receptor agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IP-Rezeptor-Agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lösliche Guanylatzyklase</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Phosphodiesterase type 5 inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Phosphodiesterase-Typ-5-Inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostacyclin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostazyklin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Soluble guanylyl cyclase</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weigand, Markus A.</subfield><subfield code="d">1967-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1064970435</subfield><subfield code="0">(DE-627)815375239</subfield><subfield code="0">(DE-576)424658666</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Der Anaesthesist</subfield><subfield code="d">Berlin : Springer, 1994</subfield><subfield code="g">65(2016), 8, Seite 635-652</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)253389771</subfield><subfield code="w">(DE-600)1458421-9</subfield><subfield code="w">(DE-576)072283122</subfield><subfield code="x">1432-055X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:635-652</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s00101-016-0207-y</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/s00101-016-0207-y</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2339</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2414</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2424</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">2016</subfield><subfield code="e">8</subfield><subfield code="h">635-652</subfield><subfield code="g">18</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">3028880024</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">16-10-18</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2016</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_9</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_18</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1497922607</subfield><subfield code="a">Weigand, Markus A.</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416740848</subfield><subfield code="a">Chirurgische Universitätsklinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_6</subfield></datafield></record></collection>
|
| standort_str_mv |
--%%-- |
| standort_iln_str_mv |
2013:--%%-- DE-16-250:--%%-- |
| author |
Sommer, Natascha 1974- |
| spellingShingle |
Sommer, Natascha 1974- misc Endothelin receptor antagonists misc Endothelinrezeptorantagonist misc IP receptor agonist misc IP-Rezeptor-Agonist misc Lösliche Guanylatzyklase misc Phosphodiesterase type 5 inhibitors misc Phosphodiesterase-Typ-5-Inhibitor misc Prostacyclin misc Prostazyklin misc Soluble guanylyl cyclase 2013 hd2016 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_9 2013 s_18 2013 Weigand, Markus A. 2013 Chirurgische Universitätsklinik 2013 Verfasser 2013 pos_6 Pulmonale Hypertonie was ist neu in der Therapie? |
| authorStr |
Sommer, Natascha 1974- |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)253389771 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| typewithnormlink_str_mv |
DifferentiatedPerson@(DE-588)129248916 Person@(DE-588)129248916 Person@(DE-588)1064970435 DifferentiatedPerson@(DE-588)1064970435 |
| collection |
KXP SWB GVK |
| remote_str |
true |
| last_changed_iln_str_mv |
2013@16-10-18 |
| illustrated |
Not Illustrated |
| issn |
1432-055X |
| topic_title |
2013 01 DE-16-250 00 s hd2016 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_9 2013 01 DE-16-250 03 s s_18 2013 01 DE-16-250 04 p (DE-627)1497922607 Weigand, Markus A. 2013 01 DE-16-250 04 k (DE-627)1416740848 Chirurgische Universitätsklinik 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_6 Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall Endothelin receptor antagonists Endothelinrezeptorantagonist IP receptor agonist IP-Rezeptor-Agonist Lösliche Guanylatzyklase Phosphodiesterase type 5 inhibitors Phosphodiesterase-Typ-5-Inhibitor Prostacyclin Prostazyklin Soluble guanylyl cyclase |
| topic |
misc Endothelin receptor antagonists misc Endothelinrezeptorantagonist misc IP receptor agonist misc IP-Rezeptor-Agonist misc Lösliche Guanylatzyklase misc Phosphodiesterase type 5 inhibitors misc Phosphodiesterase-Typ-5-Inhibitor misc Prostacyclin misc Prostazyklin misc Soluble guanylyl cyclase 2013 hd2016 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_9 2013 s_18 2013 Weigand, Markus A. 2013 Chirurgische Universitätsklinik 2013 Verfasser 2013 pos_6 |
| topic_unstemmed |
misc Endothelin receptor antagonists misc Endothelinrezeptorantagonist misc IP receptor agonist misc IP-Rezeptor-Agonist misc Lösliche Guanylatzyklase misc Phosphodiesterase type 5 inhibitors misc Phosphodiesterase-Typ-5-Inhibitor misc Prostacyclin misc Prostazyklin misc Soluble guanylyl cyclase 2013 hd2016 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_9 2013 s_18 2013 Weigand, Markus A. 2013 Chirurgische Universitätsklinik 2013 Verfasser 2013 pos_6 |
| topic_browse |
misc Endothelin receptor antagonists misc Endothelinrezeptorantagonist misc IP receptor agonist misc IP-Rezeptor-Agonist misc Lösliche Guanylatzyklase misc Phosphodiesterase type 5 inhibitors misc Phosphodiesterase-Typ-5-Inhibitor misc Prostacyclin misc Prostazyklin misc Soluble guanylyl cyclase 2013 hd2016 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_9 2013 s_18 2013 Weigand, Markus A. 2013 Chirurgische Universitätsklinik 2013 Verfasser 2013 pos_6 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| standort_txtP_mv |
--%%-- |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Der Anaesthesist |
| normlinkwithtype_str_mv |
(DE-588)129248916@DifferentiatedPerson (DE-588)129248916@Person (DE-588)1064970435@Person (DE-588)1064970435@DifferentiatedPerson |
| hierarchy_parent_id |
253389771 |
| signature |
--%%-- |
| signature_str_mv |
--%%-- |
| hierarchy_top_title |
Der Anaesthesist |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)253389771 (DE-600)1458421-9 (DE-576)072283122 |
| normlinkwithrole_str_mv |
(DE-588)129248916@@aut@@ (DE-588)1064970435@@aut@@ |
| title |
Pulmonale Hypertonie was ist neu in der Therapie? |
| ctrlnum |
(DE-627)1581951477 (DE-576)511951477 (DE-599)BSZ511951477 (OCoLC)1341020112 |
| title_full |
Pulmonale Hypertonie was ist neu in der Therapie? N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall |
| author_sort |
Sommer, Natascha 1974- |
| journal |
Der Anaesthesist |
| journalStr |
Der Anaesthesist |
| callnumber-first-code |
- |
| lang_code |
ger eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| container_start_page |
635 |
| author_browse |
Sommer, Natascha Weigand, Markus A. |
| selectkey |
2013:l |
| container_volume |
65 |
| physical |
18 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sommer, Natascha |
| title_sub |
was ist neu in der Therapie? |
| doi_str_mv |
10.1007/s00101-016-0207-y |
| normlink |
129248916 391469665 188399836 1064970435 815375239 424658666 1410508463 1497922607 1416740848 1410501914 |
| normlink_prefix_str_mv |
(DE-588)129248916 (DE-627)391469665 (DE-576)188399836 (DE-588)1064970435 (DE-627)815375239 (DE-576)424658666 (DE-627)1410508463 (DE-627)1497922607 (DE-627)1416740848 (DE-627)1410501914 |
| author2-role |
verfasserin |
| title_sort |
pulmonale hypertoniewas ist neu in der therapie? |
| title_auth |
Pulmonale Hypertonie was ist neu in der Therapie? |
| abstract |
Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 |
| abstractGer |
Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 |
| abstract_unstemmed |
Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency. Paralleltitel von der Frontdoor übernommen Mit engl. Zusammenfassung Gesehen am 16.10.2018 |
| collection_details |
GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_267 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2339 GBV_ILN_2414 GBV_ILN_2424 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
8 |
| title_short |
Pulmonale Hypertonie |
| url |
http://dx.doi.org/10.1007/s00101-016-0207-y https://doi.org/10.1007/s00101-016-0207-y |
| ausleihindikator_str_mv |
2013:- |
| rolewithnormlink_str_mv |
@@aut@@(DE-588)129248916 @@aut@@(DE-588)1064970435 |
| remote_bool |
true |
| author2 |
Weigand, Markus A. 1967- |
| author2Str |
Weigand, Markus A. 1967- |
| ppnlink |
253389771 |
| GND_str_mv |
Sommer, Natascha Weigand, M. A. Weigand, Markus Alexander Michael Weigand, Marcus A. Weigand, Markus Weigand, Markus A. |
| GND_txt_mv |
Sommer, Natascha Weigand, M. A. Weigand, Markus Alexander Michael Weigand, Marcus A. Weigand, Markus Weigand, Markus A. |
| GND_txtF_mv |
Sommer, Natascha Weigand, M. A. Weigand, Markus Alexander Michael Weigand, Marcus A. Weigand, Markus Weigand, Markus A. |
| title_alt |
Pulmonary hypertension$dwhat is new in therapy? |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00101-016-0207-y |
| callnumber-a |
--%%-- |
| up_date |
2024-07-04T19:23:31.842Z |
| _version_ |
1803677610117431296 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1581951477</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20220815032133.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181016s2016 xx |||||o 00| ||ger c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00101-016-0207-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1581951477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-576)511951477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BSZ511951477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1341020112</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ger</subfield><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sommer, Natascha</subfield><subfield code="d">1974-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)129248916</subfield><subfield code="0">(DE-627)391469665</subfield><subfield code="0">(DE-576)188399836</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pulmonale Hypertonie</subfield><subfield code="b">was ist neu in der Therapie?</subfield><subfield code="c">N. Sommer, M. Hecker, K. Tello, M. Richter, C. Liebetrau, M.A. Weigand, W. Seeger, A. Ghofrani, H. Gall</subfield></datafield><datafield tag="246" ind1="3" ind2="3"><subfield code="a">Pulmonary hypertension$dwhat is new in therapy?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">4. August 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">18</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Paralleltitel von der Frontdoor übernommen</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Mit engl. Zusammenfassung</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Gesehen am 16.10.2018</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pulmonary hypertension (PH) comprises a group of pulmonary vascular diseases that are characterized by progressive exertional dyspnea and right heart insufficiency ultimately resulting in right heart decompensation. The classification is into five clinical subgroups that form the absolutely essential basis for decisions on the indications for different pharmacological and non-pharmacological forms of treatment. The guidelines were updated in 2015 and in addition to the hitherto existing pharmacological treatment options of phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclins, the soluble guanylate cyclase stimulator riociguat has now been incorporated for treatment of certain forms of PH. This article provides an overview of the new treatment recommendations in the current guidelines, e. g. for PH patients who are in intensive care units due to surgical interventions or progressive right heart insufficiency.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelinrezeptorantagonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IP receptor agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IP-Rezeptor-Agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lösliche Guanylatzyklase</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Phosphodiesterase type 5 inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Phosphodiesterase-Typ-5-Inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostacyclin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostazyklin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Soluble guanylyl cyclase</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weigand, Markus A.</subfield><subfield code="d">1967-</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1064970435</subfield><subfield code="0">(DE-627)815375239</subfield><subfield code="0">(DE-576)424658666</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Der Anaesthesist</subfield><subfield code="d">Berlin : Springer, 1994</subfield><subfield code="g">65(2016), 8, Seite 635-652</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)253389771</subfield><subfield code="w">(DE-600)1458421-9</subfield><subfield code="w">(DE-576)072283122</subfield><subfield code="x">1432-055X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:635-652</subfield><subfield code="g">extent:18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s00101-016-0207-y</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/s00101-016-0207-y</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2339</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2414</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2424</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">2016</subfield><subfield code="e">8</subfield><subfield code="h">635-652</subfield><subfield code="g">18</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">3028880024</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">16-10-18</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2016</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_9</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_18</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1497922607</subfield><subfield code="a">Weigand, Markus A.</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416740848</subfield><subfield code="a">Chirurgische Universitätsklinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_6</subfield></datafield></record></collection>
|
| score |
7.3990564 |